Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965675 · ClinicalTrials.gov registry record · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
A Phase 3 study of Chronic Migraine in Children, sponsored by H. Lundbeck A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT04965675: Recruiting Phase 3 study of Chronic Migraine in Children, sponsored by H. Lundbeck A/S.
NCT04965675 is a Phase 3 study of Chronic Migraine in Children that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 285 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04965675, a Phase 3 study of Chronic Migraine in Children, is actively recruiting participants, sponsored by H. Lundbeck A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eptinezumab
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
- AGA Clinical Trials - Hialeah
- Axcess Medical Research - Loxahatchee Groves
- University of South Florida - Tampa
Michigan
- Michigan Head Pain and Neurological Institute - Ann Arbor
- Michigan State University - Department of Neurology - East Lansing
- Corewell Health Butterworth Hospital - Grand Rapids
Connecticut
- Yale-New Haven Children's Hospital - PIN - New Haven
- Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford
New York
- Dent Neurosciences Research Center Incorporated - Amherst
- North Suffolk Neurology-Commack - Commack
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Clinical Integrative Research Center of Atlanta - Atlanta
Kentucky
- University of Kentucky HealthCare (UKHC) Kentucky Clinic - Lexington
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
What NCT04965675 shows while recruiting
NCT04965675 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Chronic Migraine in Children appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04965675 names 20 study sites across 13 states, led by Florida, Michigan, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04965675 about?
NCT04965675 is a clinical study titled "A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine". To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
What is the current status of trial NCT04965675?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2021-06-30. Estimated completion is 2026-10-31.
What conditions does trial NCT04965675 study?
This clinical trial studies the following conditions: Chronic Migraine in Children.
What interventions are being tested in trial NCT04965675?
The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT04965675?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04965675 being conducted?
This trial has 20 study locations across Connecticut, District of Columbia, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04965675's enrollment target sits among peer trials
285 1186th of 2000 higher than 812 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
- NCT06144164 · 285 participants · Phase 3
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI